IONIS PHARMACEUTICALS INCIONS
Market cap
$12.9B
P/E ratio
| 2010/12 | 2011/12 | 2012/12 | 2013/12 | 2014/12 | 2015/12 | 2016/12 | 2017/12 | 2018/12 | 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | |
| Stock-based compensation | 12 | 10 | 9 | 11 | 31 | 59 | 72 | 86 | 131 | 147 | 230 | 121 | 100 | 106 | 130 |
| Cash from operations | -64 | -115 | 2 | 63 | 6 | 21 | -112 | 174 | 603 | 346 | 36 | 31 | -274 | -308 | -501 |
| Capital expenditures | -13 | -7 | -1 | -2 | -8 | -8 | -7 | -35 | -14 | -31 | -35 | -12 | -16 | -24 | -45 |
| Cash from investing | 24 | 111 | 18 | -256 | -83 | -60 | 57 | -358 | -930 | -41 | 274 | 195 | -263 | -214 | -134 |
| Repurchases of common stock | - | - | - | - | - | - | - | - | - | 34 | 91 | - | - | - | - |
| Cash from financing | 5 | -1 | 39 | 228 | 60 | 25 | 11 | 229 | 476 | 100 | -597 | 246 | -55 | 644 | 478 |
| Free cash flow | |||||||||||||||
| FCF margin (%) |